echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bayer's ErSO therapy for metastatic breast cancer has not yet entered clinical trials

    Bayer's ErSO therapy for metastatic breast cancer has not yet entered clinical trials

    • Last Update: 2021-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    Previously, it was reported that ErSO, a small molecule drug from Bayer, has a 95% to 100% success rate for the treatment of cancer cells in animals
    .
    The outside world predicts that this compound is likely to be tested in humans
    .
    However, due to commercial cooperation, this therapy has not actually entered the human trial stage
    .

    This therapy ErSO is a new drug developed by researchers at the University of Illinois in the United States.
    It has been proven to be able to target and neutralize metastatic breast cancer cells in mice within a few days without recurrence.
    Can significantly reduce lung, bone and brain tumor metastasis
    .
    David Shapiro, a professor of biochemistry who developed the therapy, said, “It’s hard to imagine finding a drug that can treat cancer that can make the tumor disappear within a few days
    .

    In September 2020, Bayer signed an agreement to purchase the development license for the drug for US$370 million and cooperated with Arizona-based Systems Oncology to develop the drug
    .
    Systems Oncology will receive an advance payment of US$25 million in drug development, as well as the remaining US$345 million in sales royalties and other important related payments
    .

    However, according to the latest reports, since the partnership between the two companies is no longer effective, the two companies' cooperation project on the tumor therapy has also reached a deadlock
    .
    Bayer said in a statement that after a thorough preclinical study of ErSO, Bayer has decided to stop the development of this project
    .
    Bayer said that careful measures must be taken to ensure that compounds with potential and curative effects can help breast cancer patients
    .

    Metastatic estrogen receptor-positive breast cancer is the most common type of breast cancer, and there is currently no cure.
    ErSO can promote cancer cell death by activating the expected unfolded protein response in estrogen-positive breast cancer cells
    .
    Experimental results showed that within a few days after receiving ErSO treatment, a large number of tumor cells in multiple estrogen receptor-positive breast cancer mouse models were killed
    .
    In addition, although some tumors that have not completely resolved have re-growth after stopping the drug, they are still sensitive to retreatment with ErSO
    .
    In another mutated, patient-derived mouse model of breast tumors with low expression of estrogen receptors, oral ErSO treatment blocked tumor growth compared to standard care treatments tamoxifen and fulvestrant Even better, many breast tumors have shrunk by more than 99% within 3 days of treatment
    .

    ErSO Activism manager Danny Goss expressed his disappointment.
    “The fact is that this project was taken over by Bayer, and it looked promising at the time
    .
    Then the project reached its end after 12 months, which is very disappointing
    .
    "At the same time, there are also a large number of tumor patients who expressed disappointment.
    In the recent major progress, more than 20,000 people have signed a petition asking Bayer to restart the research and development of the project
    .
    The patient group is puzzled by what scientific reason Bayer has to stop research on drugs that can eliminate 95% or even 100% of tumors within three days, and Bayer has not announced the specific reasons for the stop
    .

    At the same time, Professor Shapiro and his team said they will continue to study ErSO therapy
    .
    Shapiro said he hopes that the development of this unique anti-cancer drug will eventually be tested in humans
    .
    At present, the next step of ErSO is still uncertain
    .

    Reference source:

    1.
    Drug That Eradicates Breast Cancer Metastasis Yet To Enter Human Trials

    2.
    Breakthrough metastatic breast cancer treatment hits snag

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.